Background: ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA).
Methods: Subjects completing the final visit in the parent phase 3 randomized, double-blind, controlled equivalence study comparing the efficacy and safety of the biosimilar ABP 501 with adalimumab reference product (RP) were enrolled in this open-label extension (OLE) study. All subjects received 40 mg ABP 501 every other week for 68 weeks. Key safety endpoints included treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and anti-drug antibody (ADA) incidences. Efficacy endpoints included ACR20 (at least 20% improvement in American College of Rheumatology core set measurements from baseline) and Disease Activity Score 28-joint count C-reactive protein (DAS28-CRP) change from baseline.
Results: Among 466/467 patients treated with ABP 501, 229 transitioned from the ABP 501 arm of the parent study (ABP 501/ABP 501) and 237 from the adalimumab RP arm (RP/ABP 501); 412/467 (88.2%) patients completed the study. The overall TEAE incidence was 63.7% (297/466); grade ≥ 3 TEAE incidence was 9.0% (42/466). The incidence of TEAEs leading to discontinuation of investigational product was 3.6% (17/466). The SAE incidence was 9.9% (46/466). Overall, 18.2% (85/466) of subjects developed binding ADAs and 6.9% (32/466) developed neutralizing ADAs in the OLE study. The ACR20 response rate was 73.3% (340/464 subjects) at OLE baseline, and 78.8% (327/415 subjects) at week 70 of the OLE study. The overall mean DAS28-CRP change from the parent study baseline was - 2.25 at the OLE study baseline (n = 440), - 2.36 at week 4 (n = 463), - 2.41 at week 24 (n = 450), - 2.55 at week 48 (n = 433), and - 2.60 at week 70 (n = 412). Efficacy was maintained throughout the study.
Conclusions: Efficacy previously demonstrated in the parent study was maintained in this OLE study with no new safety findings. Long-term safety, immunogenicity, and efficacy were similar in the ABP 501/ABP 501 and RP/ABP 501 groups. The single switch from RP to ABP 501 did not impact immunogenicity.
Trial Registration: ClinicalTrial.gov, NCT02114931.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440148 | PMC |
| http://dx.doi.org/10.1186/s13075-019-1857-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cost-Effectiveness of Biosimilars vs Leflunomide in Patients With Rheumatoid Arthritis.
JAMA Netw Open
June 2024
Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Article Synopsis
- A study found that for rheumatoid arthritis patients who didn't respond to methotrexate, starting treatment with biosimilar DMARDs (like biosimilar infliximab) resulted in better clinical outcomes than conventional DMARDs, but cost-effectiveness data is still uncertain.
- The aim was to assess the cost-effectiveness of starting biosimilar DMARD treatment after methotrexate failure compared to leflunomide, utilizing a Markov model to simulate long-term disease progression and costs based on local patient data from Hong Kong.
- The analysis revealed that treating with leflunomide resulted in higher lifetime healthcare costs and fewer quality-adjusted life-years (QALYs) than bios
Article Synopsis
- ABP 501 is an adalimumab biosimilar approved for immune-mediated inflammatory diseases like rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and a study was conducted to analyze its treatment patterns in Germany and France.
- The study included patients who started ABP 501 between October 2018 and March 2020, tracking their persistence and switching behavior based on prior experience with adalimumab products over a year.
- Results showed varying persistence rates among different diseases and countries, with experienced patients often switching back to the original adalimumab, indicating a potential nocebo effect, and highlighting the need for further research.
Development of Morphea Following Treatment with an ADA Biosimilar: A Case Report.
Curr Rheumatol Rev
June 2024
Department of Rheumatology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
Article Synopsis
- - TNFα is a key cytokine linked to inflammatory diseases like rheumatoid arthritis and has led to the development of TNFα inhibitors (TNFi) which improve treatment outcomes, but they can also cause unusual autoimmune responses and skin issues.
- - A case study describes a 58-year-old woman with seronegative RA who developed a deep skin lesion resembling morphea after starting treatment with a TNFi biosimilar, ABP-501, which improved significantly after the medication was stopped.
- - This case highlights the need for healthcare providers to monitor patients on TNFi biosimilars for paradoxical reactions such as morphea, stressing the importance of thorough clinical examinations and follow-ups.
Treatment persistence and switching patterns of ABP 501 in European patients with inflammatory bowel disease.
Therap Adv Gastroenterol
January 2024
Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Article Synopsis
- - The study evaluated real-world usage of the adalimumab biosimilar ABP 501 for treating inflammatory bowel disease (IBD) by analyzing pharmacy claims data from Germany and France.
- - It included 3362 German and 733 French patients, finding that 54.4% in Germany and 65.3% in France were new to ADA products; median treatment persistence varied between groups, with ADA-naïve patients showing slightly shorter persistence times.
- - Around 53.7% of German patients and 51.0% of French patients adhered to ABP 501 during the first year, while approximately 20% switched to other therapies, often to the original adalimumab reference product
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!